Hepatitis B infection is endemic in many parts of the world (1). Measurement of hepatitis B viral DNA polymerase (DNA nucleotidyltransferase, EC 2.7.7.7) in serum is important in assessing the stage of infection: because the enzyme is found only in the virus (2), its detection indicates the presence of the infectious particle in blood. The usual method of measuring hepatitis B viral DNA polymerase requires separation of viral particles from serum by ultracentrifugation, followed by serological tests to ensure specificity (3, 4). Recently, an assay method was reported (5) in which the inhibition by phosphonoformic acid (PFA) of nucleotide incorporation is a measure of hepatitis B viral DNA polymerase activity.4 The PFA inhibition assay eliminated the need for serological checks, but entailed a 6-h ultracentrifugation step of 6-mL serum samples.
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removed by washing the precipitate. The difference in the amount of 32P incorporated in the absence of PFA and that in its presence is a measure of hepatitis B viral DNA polymerase activity. PFA also inhibits DNA polymerases from other viruses, including cytomegalovirus, herpes simplex virus, and Epstein-Barr virus (6, 7) but these viruses are not found in blood in numbers that permit their detection by means of their DNA polymerase activity. Thus the PFA inhibition assay of serum is considered to be specific for hepatitis B viral DNA polymerase.
Materials and Methods

Reagents
Except where specified, chemicals were obtained from Sigma Chemical Co., St. Louis, MO.
PFA, 7.5 mmol/L. Dissolve 22.5 mg of the trisodium salt of PFA hexahydrate in 10 mL of water.
Detergent and antioxidant.
Per liter, 50 mL of"Nonidet P-40," and 5 mL of 2-mercaptoethanol.
Nomdet P-40 is octylphenoxypolyethoxyethanol. 
Buffer
Trichioroacetic acid (TCA)-pyrophosphate.
Dissolve 100 g of TCA and 53.2 g of anhydrous Na4P2O7 in water; dilute to 2 L. Scintillation fluid. Mix 1 L of "Lipotron" with 100 mL of "Solutron" and 20 niL of water (both products of Kontron AG, Zurich, Switzerland).
Store the PFA and TCA solutions at 4#{176}C, the scintillation fluid at room temperature, and all other reagents at -20 #{176}C.
Other materials. 
Specimens
We used serum from volunteers who were undergoing serological screening in a hepatitis B vaccination program. Plasma from blood-bank specimens that had been rejected because of the presence of HBsAg was also used. Blood-bank plasma was recalcified before use in order to complex the through step 5. Radioactivity of the precipitates was counted in a gamma counter. Assays with [31{]dCTP were performed as described elsewhere (5) . In both experiments, we used 2 Ci of radioisotope per tube, as above. Figure 1 shows the time course of [32P]dCTP incorporation into TCA-insoluble constituents of serum. PFA had no effect on P incorporation in uninfected serum, but hepatitis B-infected serum typically showed pronounced effects. The dosage of added PFA (nominal final concentration, 1 mmol/L) inhibited more than 90% of the viral enzyme but none of the human DNA polymerases in serum (5) . Relatively high amounts of P were incorporated, both in uninfected serum and in infected serum incubated in the presence of PFA.
Results
The time course of PFA-inhibitable nucleotide incorporation was curvilinear ( Figure 2 ). Use of a shorter incubation period might have produced a more nearly linear curve, but radioactivity counting rates (cpm) for samples would be lower and the assay would be less sensitive. The amount of PFA-inhibitive nucleotide incorporation was consistently greater after 2 h than after 1 h, but changes observed during the third hour were more variable, as shown by the disproportionately larger SD. Because of the nonlinear kinetics, we express hepatitis B DNA polymerase activity as nU/L to denote the average rate of incorporation in a 2-h incubation period.
8000
citrate that would otherwise have bound Mg2. Serum was stored at -20 #{176}C.
Serological markers for hepatitis B virus infection were tested with commercial enzyme-linked immuno-absorbant assay kits (Abbott Laboratories, N. Chicago, IL): AUS-ZYME II, AUSAB-ELA, CORZYM, and HBe-EIA for HBsA, anti-HBs, anti-HBc, and HBeAg, respectively. Keep the mixture at 4#{176}C. 3. Add 20 L of the radioactive mixture that was prepared in Step 2 to the tubes prepared in Step 1. Vortex-mix and place the tubes in a bath at 37 #{176}C for 2 h. Then transfer the tubes to an ice bath (4#{176}C) and add 1 mL of ice-cold TCApyrophosphate. Vortex-mix the tubes' contents and let them stand in an ice bath for 1 h.
4. Centrifuge the contents of the tubes at 1000 x g for 10 mm at room temperature.
After placing the tubes in an ice bath, aspirate the supernates with a Pasteur pipet that is connected to a suction flask for collecting radioactive waste fluids.
5. To each tube add 2 mL of ice-cold TCA-pyrophosphate. Vortex-mix until the disc of precipitated serum is lifted off the bottom of the tube. The efficiency of washing is not improved by breaking up the disc. Centrifuge the tubes and their contents at 1000 x g for 5 mm. Again place the tubes in an ice bath and aspirate the supernates. Repeat step 5 three more times.
6. Add to each tube 1.5 mL of scintillation fluid and vortex-mix. Transfer the entire contents of each tube to a 5-mL scintillation vial. Wash each tube with two more 1.5-niL portions of scintillation fluid, and add the washes to the vial. Let the vials stand overnight, and shake them the next day to disperse the precipitate.
7. Measure the radioactivity with a liquid scintillation counter, counting for 5 mm per vial (counting efficiency, 100%; estimated SD of PFA-inhibitive radioactivity per specimen at 8000 and 2000 cpm is 1.4% and 2.8%, respectively). The, counts per minute are corrected for radioactive decay to the reference date, by use of standard tables. After calculating the difference in radioactivity incorporated in the absence and presence of PFA, multiply by the factor F to obtain hepatitis B viral DNA polymerase activity, in nUlL. F = (4)(106 LfL)(1 dpmlcpm)(1000 nU . min/pmol) (30 L)(120 min)(2220 dpmlnCi)(specifIc activity)
For the 132P]dCTP we used, the specific activity was 7000 nCilpmol, so that F = 0.0715 nUlL cpm. Where the difference in 32P incorporation with and without PFA was a small negative value, as was sometimes the case, we used a result of zero.
Other Procedures
Assays with I-labeled dCTP were performed as above, group. Results in infected cases ranged from 0 to 665 nUlL (0 to 9300 cpm), with a median value of 100 nU/L (1400 cpm). Four of the infected serum specimens repeatedly fell below the cutoff value. These points could represent false negatives or they could reflect the absence of virus (see Discussion).
We evaluated the precision of the micromethod with sera having different amounts of viral DNA polymerase activity ( Table 1) . As expected, the CV increased at lower enzymic activity. Specimens of HBsAg-positive serum that had less than 500 cpm of activity (about one in eight) were usually retested. The mean difference between two successive tests on the same serum was about 140 cpm or 10 nU/L.
We compared results with those by our previous method (5), using [3H]dCTP as the radioactive precursor, for 16 specimens of recalcified HBsAg-positive plasma. As Table 2 shows, the correlation between the two methods was excellent, and the radioactivity counting rates in the macro- Table 2 summarizes the results for 23 serum specimens that were analyzed with the two radiolabeled nucleotides.
The results obtained with 'I-labeled dCTP were disappointing, generally yielding lower sample counting rates than would be expected from their specific activities. The correlation of results with those obtained by the 32P-labeled nucleotide was only r = 0.75. We attribute the poor performance of the 'I-labeled dCTP to several factors: its lesser radiochemical purity, its greater chemical instability, and the demonstrable inhibitive effect of the iodide ion (one of its decomposition products) on DNA polymerase activity. Despite its usefulness in similar applications (9) we concluded that '251-labeled dCTP was unsuitable for the assay of hepatitis B viral DNA polymerase.
Discussion
The key change in converting the PFA inhibition assay to a micromethod was the use of radiolabel of high specific activity to offset the effect of decreasing the size of the serum sample. A commercially produced [32PIdCTP ifiled this requirement, and had the added advantage of greater counting efficiency than was obtained with E3H]dCTP.
However, the rate of nucleotide incorporation was decreased as the result of the low concentration of dCTP (4 nmol/L), so that we had to establish a new reference interval for the micromethod. Eliminating the ultracentrifugation step probably increased the fraction of viral particles assayed, given the incomplete sedimentation of the virus under specified conditions (5) . The overall effect of these positive and negative factors was that PFA-inhibitive radioactivity incorporated in the samples in the macro-and micromethods was comparable, and there was no loss of sensitivity in adopting the micromethod.
The sensitivity of the proposed assay is about the same as that of another test for the presence of the virus, molecular hybridization to hepatitis B DNA. Independent estimates of the proportion of HBeAg-positive blood specimens that contain hepatitis B DNA or viral DNA polymerase agree closely and suggest that virus may be absent in about 10-15% of this group. Molecular hybridization tests carried out in two laboratories showed 84 to 88% of HBeAg-positive sera to be positive also for hepatitis B DNA (10, 11) . The remainder showed equivocal or negative results. This compares with our previous report that about 85% of HBeAgpositive blood specimens contain PFA-inhibitive DNA polymerase activity (5) . The micromethod provides similar results, detecting about 90% (37/4 1) of HBeAg-positive serum tested in the present study as having hepatitis B DNA polymerase activities above the cutoff value.
